Physicians with the Personalized Medicine Program at The Tisch Cancer Institute have initiated a phase I proof - of - concept study, a fully personalized multipeptide
therapeutic vaccine designed to target tumor - derived neoantigens for individual patients.
Not exact matches
The heart disease shot Some of the new
therapeutic vaccines are actually
designed to attack the body, albeit in a selective way.
Therapeutic vaccines are
designed to elicit an immune response against tumor - specific or tumor - associated antigens, encouraging the immune system to attack cancer cells bearing these antigens.
Using enhanced DNA technology, the lab has
designed DNA
vaccines that drive immune responses in prophylactic or
therapeutic settings against Human Immunodeficiency Virus (HIV), Dengue (DV), Chikungunya virus (CHIKV), Middle Eastern Respiratory Syndrome (MERS) virus, and Zika Virus (ZV).
Therapeutic cancer
vaccines are
designed to elicit an immune response against tumor - specific or tumor - associated antigens, encouraging the immune system to attack cancer cells bearing these antigens.
«Seeing the
design of this key protein provides a target for a potential
vaccine or even a
therapeutic drug,» Smith said.